• Find people
• Intranet

Molecular cancer therapeutics Joan Albanell

Publications 2026 (8)

• Mirallas O^*, Ruiz Pace F, Velilla G, Gómez-Puerto D, Gorría T, Yaringaño J, Martinez-Monino A, López-Valbuena D, Vaz MA, Hernandez A, Martínez-Saez E, Aguado Sorolla M, Castro-Henriques M, Lostes Bardaji J, Di Muzio A, Gallego O, Martínez-García M, Domenech M, Carles J, Balaña C, Pineda E, Dienstmann R, Sepulveda JM, Vieito M. Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study. NPJ PRECIS ONCOL 2026; 10(1): 46.
  Cites:1
  Cites:1
• Oliveira M^*, Ciruelos E, Villacampa G, Morales S, Salvador-Bofill J, QUIROGA V, Gavilá J, Cortegoso A, Vega E, Henao F, Servitja S, Tolosa P, Chillara S, Bergamino M, Salvador F, Paes-Dias M, Ferrero-Cafiero JM, Gonzalez-Farre X, Pascual T, Saura C. Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clin Cancer Res 2026; 32(3): 468-478.
  Cites:0
  Cites:0
• Martínez Ciarpaglini C, Ortega M, Pérez Buira S, Bolea A, Casado B, Herencia Bellido C, Tornero Piñero P, Naranjo Hans D, Palomar B, Quiceno H, Sardón Fernández A, Torner Calvo A, Rojo F^*, Iglesias Coma M. CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients. Virchows Arch 2026; 487(6): 1337-1346.
  Cites:1
  Cites:1
• Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer A^*. A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study. Clin Transl Oncol 2026; 28(3): 1040-1048.
  Cites:1
  Cites:1
• Cueva JF, Palacio I, Churruca C, Herrero A, Pardo B, Constenla M, Santaballa A, Manso L, Estévez-García P, Legeren M, Marquina G, De Juan A, Quintana JF, González-Santiago S, Cassinello J, Reche P, Soriano ML, Valero M, Gaba L, Gordón MD, Gómez-Raposo C, Hernando S, Márquez R, Fuentes J, Alarcón J, Taus A, Caballero C, Corbellas M, Iriarte E, González-Martín A. Clinical outcomes and subsequent therapy in patients with platinum-sensitive recurrent ovarian cancer deriving long-term benefit from maintenance niraparib: a subgroup analysis of the GEICO-88R study. Int J Gynecol Cancer 2026; 35(11): 102116.
  Cites:0
  Cites:0
• Tolosa P^*, García-Fructuoso I, Pascual T, Martínez-Saez O, Cejalvo JM, Servitja S, Fernández-Abad M, Benitez-Fuentes JD, Brasó F, Sanfeliu E, Lema L, Ruano Y, Parrilla L, Roncero AM, Cobos MÁ, Diaz I, Centelles-López KA, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E^*. Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. Breast Cancer Res Tr 2026; 216(2): 21.
  Cites:0
  Cites:0
• Espinós-Ramírez C^*, Castellví P, Martínez-Rodríguez D, Raynard M, Viscasillas-Draper B, Masgoret P, Rodríguez-Cosmen C, Subirana-Giménez L, Martínez-García M, Mestres G, Melo M, Nebot-Galindo A, Montero-Gaig N, Sánchez-Migallón V, Valencia-Royo D, Pacheco-Comino NL, Bermejo-Perez I, Santos-Farré C, Toll-Salillas L, Alonso-Gelabert A, Homs M, Ribas P, Teixell C, Plaza-Moral AM, Tena B, Fernández Castiñeira, Armengol-Gay M, Fort-Pelai B, García-Bartoló C, Mestre-Iniesta C, Peig-Font A, Esteller PG, Clave JL, Gasca-Pera S, Batalla A, Raudá V, Roca-Amatria G. Acute Postoperative Pain After Caesarean Section, Intensity and Management: A Cohort Multicentre Study. Eur J Pain 2026; 30(1): e70183.
  Cites:2
  Cites:2
• Palomeque JA, Serra-Mir G, Blasco-Benito S, Brunel-Montaner H, Torren-Duran P, Pérez I, Cannata C, Comerma L, Menéndez S, Servitja S, Martos T, Castro-Henriques M, Borges RL, López Velazco JI, Manzano S, Duro S, Arribas J, Caffarel MM, Urruticoechea A, Seoane JA, Morey L, Albanell J, Celià-Terrassa T. Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer. J Clin Invest 2026; 136(2): e193153 (Acceptat).
  Cites:2
  Cites:2